The model is the first release in OpenAI’s Life Science model series.
OpenAI has announced plans to roll out an early version of GPT-Rosalind, its AI reasoning model designed to support research across biology, drug discovery and translational medicine.
In a statement on Thursday (16 April), OpenAI explained that on average, it can take up 15 years to move from target discovery to regulatory approval for a new drug in the US, with progress impacted by the difficulty of the underlying science, as well as the complexity of the research workflows.
The organisation said: “Scientists must work across large volumes of literature, specialised databases, experimental data and evolving hypotheses in order to generate and evaluate new ideas. These workflows are often time-intensive, fragmented and difficult to scale.”
Named after Rosalind Franklin, a pioneering figure in the field of DNA, GPT‑Rosalind is now available as a research preview in ChatGPT, Codex and the API for qualified customers through OpenAI’s access programme such as Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific.
